Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Soberana 02 with or without Soberana Plus booster for prevention of COVID-19
IRCT20210303050558N1Phase 3Completed
- Sponsor
- Pasteur Institute of Iran
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of PastoCovac and FINLAY-FR-1A in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Pasteur Institute of Iran. Primary endpoints: PCR-confirmed COVID-19 after two-dose regimen and PCR-confirmed COVID-19 after two-dose plus booster regimen. Started Apr 2021; status: completed.
02
Drugs
PastoCovacFINLAY-FR-1A
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20210303050558N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210303050558N1.